SEC 13F Intelligence

Orbimed Advisors LLC / PRLD

Orbimed Advisors LLC’s Prelude Therapeutics Inc Position

Does Orbimed Advisors LLC own Prelude Therapeutics Inc (PRLD)? Yes10.91M shares worth $37M (+0.74% of its 13F portfolio) as of Q1 2026.

Position Value
$37M
Q1 2026
Shares
10.91M
% of Portfolio
+0.74%
Quarters Held
23
currently held

Position History PRLD

Reported value by quarter
Q3 ’20: $470MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $435MQ2 ’21: $287MQ2 ’21Q3 ’21: $314MQ4 ’21: $125MQ1 ’22: $69MQ1 ’22Q2 ’22: $52MQ3 ’22: $66MQ4 ’22: $61MQ4 ’22Q1 ’23: $57MQ2 ’23: $49MQ3 ’23: $34MQ3 ’23Q4 ’23: $47MQ1 ’24: $52MQ2 ’24: $42MQ2 ’24Q3 ’24: $23MQ4 ’24: $14MQ1 ’25: $8MQ1 ’25Q2 ’25: $9MQ3 ’25: $16MQ4 ’25: $32MQ4 ’25Q1 ’26: $37Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202610.91M$37M+0.74%
Q4 202510.91M$32M+0.65%
Q3 202510.91M$16M+0.37%
Q2 202510.91M$9M+0.22%
Q1 202510.91M$8M+0.20%
Q4 202410.91M$14M+0.29%
Q3 202410.91M$23M+0.41%
Q2 202410.91M$42M+0.82%
Q1 202410.91M$52M+0.95%
Q4 202310.91M$47M+0.93%
Q3 202310.91M$34M+0.72%
Q2 202310.91M$49M+0.89%
Q1 202310.04M$57M+1.12%
Q4 202210.04M$61M+1.16%
Q3 202210.04M$66M+1.23%
Q2 202210.04M$52M+0.95%
Q1 202210.04M$69M+1.12%
Q4 202110.04M$125M+1.61%
Q3 202110.04M$314M+3.45%
Q2 202110.04M$287M+2.91%
Q1 202110.04M$435M+4.07%
Q4 202015.59M$1.1B+9.76%
Q3 202015.59M$470M+5.91%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Orbimed Advisors LLC’s full portfolio or all institutional holders of PRLD.